US Bancorp DE boosted its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 30.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 359,597 shares of the company's stock after acquiring an additional 83,463 shares during the quarter. US Bancorp DE's holdings in Kenvue were worth $8,623,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Pittenger & Anderson Inc. purchased a new position in shares of Kenvue during the 1st quarter valued at approximately $30,000. TruNorth Capital Management LLC purchased a new position in shares of Kenvue during the 1st quarter valued at approximately $36,000. Bank Julius Baer & Co. Ltd Zurich boosted its stake in shares of Kenvue by 120.6% during the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company's stock valued at $41,000 after buying an additional 929 shares during the last quarter. Clarity Asset Management Inc. purchased a new position in shares of Kenvue during the 4th quarter valued at approximately $45,000. Finally, Continuum Advisory LLC boosted its stake in shares of Kenvue by 2,071.1% during the 1st quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock valued at $47,000 after buying an additional 1,864 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.
Kenvue Trading Up 0.7%
NYSE:KVUE opened at $21.60 on Monday. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.63. Kenvue Inc. has a 1-year low of $18.10 and a 1-year high of $25.17. The firm has a market capitalization of $41.44 billion, a price-to-earnings ratio of 39.27, a price-to-earnings-growth ratio of 3.62 and a beta of 0.83. The stock has a fifty day simple moving average of $21.82 and a 200 day simple moving average of $22.40.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The business had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. During the same quarter last year, the company posted $0.28 EPS. Kenvue's revenue for the quarter was down 3.9% on a year-over-year basis. Sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th will be paid a $0.2075 dividend. The ex-dividend date of this dividend is Wednesday, August 13th. This represents a $0.83 annualized dividend and a yield of 3.8%. This is an increase from Kenvue's previous quarterly dividend of $0.21. Kenvue's dividend payout ratio (DPR) is currently 149.09%.
Analyst Ratings Changes
Several research firms recently issued reports on KVUE. Citigroup dropped their price target on Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research report on Tuesday, July 15th. UBS Group dropped their price target on Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a research report on Thursday, July 17th. JPMorgan Chase & Co. dropped their price target on Kenvue from $27.00 to $26.00 and set an "overweight" rating on the stock in a research report on Friday, July 25th. Redburn Atlantic began coverage on Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target on the stock. Finally, Barclays dropped their price target on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Tuesday, July 15th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Kenvue presently has an average rating of "Hold" and an average price target of $24.79.
Check Out Our Latest Research Report on KVUE
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
